Institute for Stem Cell & Regenerative Medicine

at the University of Washington

Quellos High Throughput Screening Core

The Quellos High Throughput Screening (HTS) Core specializes in Functional Genomics as well as Drug Discovery and Small-Molecule Optimization through chemical screening. It is located within the UW's Institute for Stem Cell and Regenerative Medicine at the South Lake Union Campus of the University Of Washington School Of Medicine serving Academic Institutions (e.g., Fred Hutchinson Cancer Research Center) as well as BioTechs and Pharma organizations in Washington State and nationwide. A team with industrial and academic experience is available to aid investigators in their assay optimization and screening activities. The Quellos HTS Core was created to provide “state of the art” high throughput and lab automation approaches that were once only available in large pharmaceutical organizations.

Applications of Functional Genomics and Small Molecule Screening

HTS has revolutionized the way biomedical research can be conducted by employing laboratory automation and robotics, thus enabling the functional interrogation of the entire genome and identification therapeutic drug candidates in timeframes that previously were untenable. The Quellos HTS Core enables investigators to carry out druggable genome scale screens, through the utilization of siRNAs libraries generated to target the human or mouse genome. An expanded collection of siRNAs including transcription factors is under development at the Core. This powerful approach is utilized for basic discoveries as well as identification of therapeutic targets for several diseases, including but not limited to cancer. At the Quellos HTS Core, application of siRNA screening methodology has been utilized for identifying pathways that sensitize cells to drugs, thus enabling the identification of potential biomarkers that predict drug sensitivity. Moreover, the Quellos HTS Core’s chemical library is extensive for an academic facility of this type consisting of drug-like, lead-generation entities (~120,000 compounds) covering a broad chemical space as well as a collection (2,000 entities) of all human drugs and known pharmacological agents. Cell-based and cell-free screening paradigms utilizing these chemical collections enables the generation of drug leads for further pre-clinical optimization. Finally, our FDA Approved Oncology Drug Set (obtained via the Drug Therapeutic Program of the NCI/NIH) and comprehensive human and animal experience collections enable the rapid investigation of individual samples for tailored drug sensitivities.

Hence, this UW core facility in addition to providing tools for system biology discoveries also catalyzes discovery of new therapeutic targets, their rapid validation as well as a platform for drug identification and optimization processes. The application of HTS will ultimately enable the practice of targeted treatments, a first step toward personalized medicine.

Instrumentation and Analysis

The center currently houses:
Cybio CyBi-Well Vario Liquid Handler
Beckman Coulter Biomek FX / Span8 Dual Arm Liquid Handler
Beckman Coulter Biomek FX Liquid Handler
PerkinElmer EnVision Multi-Label Detector
Matrix WellMate 8 channel Dispenser
FluidX Xrd-384 8/16 channel Dispenser
BioTek EL406 Washer/Dispenser with BioStack
GE Healthcare IN Cell 2000 Analyzer High Content Imager w/Robotic Arm
-Maintained within the facility, access provided by Randall Moon’s Laboratory, HHMI

For more information on equipment click here

Data analysis and report generation utilizing the following:
Microsoft Office
ChemBioOffice Ultra by CambridgeSoft
XLFit by idbs

The HTS Core's staff exhibits over 25 years of combined experience in the Biotechnology and Pharmaceutical Industry.

For more information on RNA Interference screening click here.
For more information on small molecule screening click here.

Contact Us

For more information about the Quellos High Throughput Screening Core click here.